New combo therapy for rare brain cancer shows promise in early trial
NCT ID NCT03719768
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 19 times
Summary
This early-phase study tested a combination of the immunotherapy drug avelumab and whole brain radiotherapy in 16 people with leptomeningeal disease, a rare condition where cancer spreads to the lining of the brain and spinal cord. The main goal was to find a safe dose and identify side effects. Researchers also looked at how the treatment affected immune cells in the spinal fluid.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.